High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma

Cancer Letters

Volumn 256, Issue 2, 2007, Pages 196-206

  Akamatsu, Norihiko ^a   Yamada, Yasuaki ^a   Hasegawa, Hiroo ^a   Makabe, Koki ^b   Asano, Ryutaro ^b   Kumagai, Izumi ^b   Murata, Ken ^c   Imaizumi, Yoshitaka ^a   Tsukasaki, Kunihiro ^a   Tsuruda, Kazuto ^a   Sugahara, Kazuyuki ^a   Atogami, Sunao ^a   Yanagihara, Katsunori ^a   Kamihira, Shimeru ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOTTORI UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bcl 2; Follicular lymphoma; IL 21

Indexed keywords

CASPASE 3; CASPASE 8; INTERLEUKIN 21 RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 21; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER GROWTH; CHROMOSOME 14; CHROMOSOME 18; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; ENZYME ACTIVATION; FOLLICULAR LYMPHOMA; GENETIC MARKER; HISTIOCYTIC LYMPHOMA; HUMAN; HUMAN CELL; KARYOTYPE; LARGE CELL LYMPHOMA; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; LYMPHOMA CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; T CELL LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CASPASE 8; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; INTERLEUKINS; JURKAT CELLS; K562 CELLS; LEUKEMIA; LYMPHOMA, FOLLICULAR; MEMBRANE POTENTIAL, MITOCHONDRIAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, INTERLEUKIN-21; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 34548670726     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.06.001     Document Type: Article

References (32)

1. Parrish-Novak J., Foster D.C., Holly R.D., and Clegg C.H. Interleukin 21 and IL-21 receptor: novel effector of NK and T cell responses. J. Leuk. Biol. 72 (2002) 856-863
2. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., and Sugamura K. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167 (2001) 1-5
3. Ozaki K., Kikly K., Michalovich D., Young P., and Leonard W.J. Cloning of a type I cytokine receptor most related to the IL-2 receptor β chain. Proc. Natl. Acad. Sci. USA 97 (2000) 11439-11444
4. Jin H., Carrio R., Yu A., and Malek T.R. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173 (2004) 657-665
5. Mehta D., Wurster A.L., Whitters M.J., Young D.A., Collins M., and Grusby M.J. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170 (2003) 4111-4118
6. Ozaki K., Spolski R., Ettinger R., Kim H.P., Wang G., Qi C.F., et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel induce of Blimp-1 and Bcl-6. J. Immunol. 173 (2004) 5361-5371
7. Leonard W.J., and Spolski R. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5 (2005) 688-698
8. Ueda M., Imada K., Imura A., Koga H., Hishizawa M., and Uchiyama T. Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells. Br. J. Haematol. 128 (2004) 169-176
9. Yamada Y., Ohmoto Y., Hata T., Yamamura M., Murata K., Tsukasaki K., et al. Features of the cytokines secreted by adult T cell leukemia cells. Leuk. Lymphoma 21 (1996) 443-447
10. Maeda T., Yamada Y., Moriuchi R., Sugahara K., Tsuruda K., Joh T., et al. Fas gene mutation in the progression of adult T cell leukemia. J. Exp. Med. 189 (1999) 1063-1071
11. Asano R., Kudo T., Makabe K., Tsumoto K., and Kumagai I. Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. FEBS Lett. 528 (2002) 70-76
12. Hasegawa H., Yamada Y., Harasawa H., Tsuji T., Murata K., Sugahara K., et al. Sensitivity of adult T-cell leukaemia lymphoma cells to tumour necrosis factor-related apoptosis-inducing ligand. Br. J. Haematol. 128 (2005) 253-256
13. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
14. Hans C.P., Weisenburger D.D., Greiner T.C., Gascoyne R.D., Delabie J., Ott G., et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 (2004) 275-282
15. Tagawa H., Suguro M., Tsuzuki S., Matsuo K., Karnan S., Ohshima K., et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 106 (2005) 1770-1777
16. Good K.L., Bryant V.L., and Tangye S.G. Kinetics of human B cell behavior and amplification of proliferative responses following stimulation with IL-21. J. Immunol. 177 (2006) 5236-5247
17. Jin H., and Malek T.R. Redundant and unique regulation of activated mouse B lymphocytes by IL-4 and IL-21. J. Leuk. Biol. 80 (2006) 1416-1423
18. de Totero D., Meazza R., Zupo S., Cutrona G., Matis S., Colombo M., et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates pro-apoptotic signals in chronic lymphocytic leukemia. Blood 107 (2006) 3708-3715
19. Brenne A.T., Ro T.B., Waage A., Sundan A., Borset M., and Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99 (2002) 3756-3762
20. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., and Darnell Jr. J.E. Stat3 as an oncogene. Cell 98 (1999) 293-303
21. Bromberg J., and Darnell Jr. J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19 (2000) 2468-2473
22. Chin T.E., Kitagawa M., Kuida K., Flavell R.A., and Fu X.Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol. Cell. Biol. 17 (1997) 5328-5337
23. Stephanou A., and Latchman D.S. STAT1 a novel regulator of apoptosis. Int. J. Exp. Pathol. 84 (2003) 239-244
24. Konforte D., and Paige C.J. Identification of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J. Immunol. 177 (2006) 8381-8392
25. Ahmed-Choudhury J., Williams K.T., Young L.S., Adams D.H., and Afford S.C. CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cell. Signal. 18 (2006) 456-468
26. Sandberg E.M., and Sayeski P.P. Jak2 tyrosine kinase mediates oxidative stress-induce apoptosis in vascular smooth muscle cells. J. Biol. Chem. 279 (2004) 34547-34552
27. Ma H.L., Whitters M.J., Konz R.F., Senices M., Young D.A., Grusby M.J., et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J. Immunol. 171 (2003) 608-615
28. Di Carlo E., Comes A., Orengo A.M., Rosso O., Meazza R., Musiani P., et al. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice. J. Immunol. 172 (2004) 1540-1547
29. Moroz A., Eppolito C., Li Q., Tao J., Clegg C.H., and Shrikant P.A. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173 (2004) 900-909
30. Kishida T., Asada H., Itokawa Y., Cui F.D., Shin-Ya M., Gojo S., et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 8 (2003) 552-558
31. W. Kindsvogel, S. Hughes, K. Bannink, M. Heipel, B. Johnson, R. Holly, et al., IL-21 enhances rituximab-mediated killing of B-lymphoma cell lines in vitro and in vivo, J. Clin. Oncol. 22 (14S) (2004) ASCO Annual Meeting Proceedings 2581.
32. J.A. Thompson, B.D. Curti, B.G. Redman, J.S. Weber, S.S. Agarwala, E.L. Sievers, Interleukin-21 (IL-21): tolerability and anti-tumor activity following two 5-day cycles in patients with stage IV melanoma (MM) or renal cell carcinoma (RCC), J. Clin. Oncol. 24 (18S) (2006) ASCO Annual Meeting Proceedings 2505.